Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors

Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors

IntroductionCombination molecular BRAF/MEK inhibitors targeted therapy has been shown to improve overall survival in patients with BRAF V600 mutated unresectable or metastatic melanoma. Most patients treated with BRAF/MEK inhibitors will experience adverse events but neurological adverse events (nAE...

Full description

Bibliographic Details
Main Authors: Charlotte Bonnefin, Fanny Duval, Marie Rouanet, Marie Kostine, Emilie Gerard
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
neurological adverse event
BRAF/MEK inhibitor
melanoma
encorafenib plus binimetinib
brachial plexus neuritis
parsonage-turner syndrome
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1268693/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1268693/full

Similar Items